Macy's Q1 Earnings Lift Outlook

Macy's Q1 earnings prompted a raised FY26 outlook on June 3, 2026 after its first year-over-year sales gain in nearly four years and luxury strength.

June 03, 2026·2 min read
View all news articles
Flat vector storefront icon merging department-store facade and spotlight to represent Macy's Q1 earnings lift.

KEY TAKEAWAYS

  • Macy's posted 3.0% comparable sales growth and its first year-over-year net-sales gain in nearly four years.
  • Company raised FY26 net-sales guidance to $21.5-$21.8B and EPS to $2.0-$2.2 per share.
  • Bloomingdale's comparable sales rose 10.2%, the banner's strongest first-quarter sales volume on record.

HIGH POTENTIAL TRADES SENT DIRECTLY TO YOUR INBOX

Add your email to receive our free daily newsletter. No spam, unsubscribe anytime.

Or subscribe with

Macy's, Inc. (M) reported its first year-over-year net sales growth in nearly four years in the fiscal first quarter of 2026, prompting the company to raise its full-year outlook on June 3, 2026. Management attributed the improvement to progress in its "A Bold New Chapter" turnaround and strong performance at Bloomingdale's.

Quarter Results and Guidance

Macy's said net sales for the quarter ended May 2, 2026, reached approximately $4.68 billion, up from about $4.60 billion a year earlier. GAAP net income was $63 million, or $0.23 per diluted share. Adjusted earnings per share (EPS) came to $0.13, roughly $0.10 above the FactSet consensus. Consolidated comparable sales, a metric tracking sales at established stores and digital channels, rose 3.0%, marking the strongest first-quarter comparable-sales growth in four years and the fourth consecutive quarter of gains. This followed a 1.8% increase in the prior quarter.

The company’s cash-flow statement showed a decrease in accounts payable and accrued liabilities alongside an increase in other current liabilities.

Macy's raised its full-year 2026 guidance, increasing the net sales range to $21.5 billion–$21.75 billion from $21.4 billion–$21.65 billion. It also lifted its EPS outlook to $2.00–$2.20 from $1.90–$2.10 and now expects comparable sales to rise 0.5%–1.2% for the year. At the time, FactSet consensus stood at $2.09 per share on $21.6 billion in revenue.

Turnaround Progress and Luxury Momentum

Management said the "A Bold New Chapter" turnaround is gaining traction across Macy's, Bloomingdale's, and Bluemercury, driven by merchandise refreshes, improved service, and a focus on affluent customers. These changes have shifted the sales mix toward luxury and premium assortments.

Comparable sales at Macy's banner stores increased 1.6% in the quarter. Bloomingdale's posted a 10.2% gain, its highest first-quarter sales volume on record, while Bluemercury rose 6.4%. Strong results at Bloomingdale's and Bluemercury offset more modest growth at Macy's banner stores.

The company raised its full-year outlook despite uneven broader consumer spending, citing resilience among higher-income shoppers and strong demand for high-end apparel, accessories, and beauty products. Management linked the improved guidance to the banner mix and execution of its turnaround strategy.

HIGH POTENTIAL TRADES SENT DIRECTLY TO YOUR INBOX

Add your email to receive our free daily newsletter. No spam, unsubscribe anytime.

Or subscribe with

Read other top news stories

Vail Resorts Q3 Earnings Cut Guidance After Poor Winter

Vail Resorts Q3 Earnings Cut Guidance After Poor Winter

Vail Resorts Q3 earnings showed weaker results after a poor western U.S. snow season and a guidance cut that could pressure shares.

Motorcar Parts Fourth Quarter Results Lift Outlook

Motorcar Parts Fourth Quarter Results Lift Outlook

Motorcar Parts Fourth Quarter results showed stronger margins and an improved fiscal outlook, sparking a sharp share rally traders will watch.

OpenAI IPO Filed; ChatGPT Recast as Platform

OpenAI IPO Filed; ChatGPT Recast as Platform

OpenAI IPO confidential S-1 filed June 8, 2026 as the company readies ChatGPT as a super app; underwriters and revenue cues will shape investor positioning.

Tango Therapeutics Vopimetostat Results Spur Phase 3

Tango Therapeutics Vopimetostat Results Spur Phase 3

Tango Therapeutics vopimetostat results push the program toward Phase 3 after strong pancreatic-cancer activity, prompting heavy share trading.

SpaceX IPO Fixes Price, Draws Heavy Demand

SpaceX IPO Fixes Price, Draws Heavy Demand

SpaceX IPO sets a fixed $135 price and drew heavy orders, creating allocation and liquidity questions that could shape first-day trading and index flows.

Cerebras Stock Climbs After Wall Street Buy Calls

Cerebras Stock Climbs After Wall Street Buy Calls

Cerebras stock rallied after nine brokerages initiated coverage on June 8, 2026, supporting a near-term rerating as analysts cited wafer-scale chips.